Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis - Workshop Summary
Ein Angebot gefunden
Bester Preis: € 2,18 (vom 06.09.2019)Aus dem Archiv:
1
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis - Workshop Summary (2012)
~EN NW EB DLISBN: 9780309265966 bzw. 0309265967, vermutlich in Englisch, National Academies Press, neu, E-Book, elektronischer Download.
Lieferung aus: Deutschland, Free shipping.
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)-a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)-face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them.This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review:-To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks.-The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain.-What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President`s Emergency Plan for AIDS Relief [PEPFAR])- The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration-Identification of potential innovative solutions to the problem, Englisch, Ebook.
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)-a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)-face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them.This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review:-To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks.-The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain.-What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President`s Emergency Plan for AIDS Relief [PEPFAR])- The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration-Identification of potential innovative solutions to the problem, Englisch, Ebook.
Daten vom 06.09.2019 10:58h
ISBN (andere Schreibweisen): 0-309-26596-7, 978-0-309-26596-6
ISBN (andere Schreibweisen): 0-309-26596-7, 978-0-309-26596-6
Zuerst gefunden: 06.09.2019 10:58:55
Zuletzt gefunden: 06.09.2019 10:59:00
Kleinster Preis: € 2,18 (vom 06.09.2019 10:58:55)
Höchster Preis: € 2,18 (vom 06.09.2019 10:58:55)
Fundstellen insgesamt: 2
Zuletzt gefunden: 06.09.2019 10:59:00
Kleinster Preis: € 2,18 (vom 06.09.2019 10:58:55)
Höchster Preis: € 2,18 (vom 06.09.2019 10:58:55)
Fundstellen insgesamt: 2
Momentan keine Suchergebnisse - vielleicht bald lieferbar
Ihre Suche nach ist bei mehr als 50 angebundenen Webshops momentan nicht lieferbar. Wir finden dieses Buch aber trotzdem innerhalb weniger Wochen.
Sie Suchen nach diesem Buch:
Board on Health Sciences Policy: Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis - Workshop Summary
ISBN: 9780309265966
Speichern Sie diese Suche kostenlos in ab, dann werden Sie automatisch benachrichtigt, sobald dieses Buch verfügbar ist. Meistens finden wir dieses Buch innerhalb weniger Wochen und verständigen Sie dann per E-Mail. Sie können dann frei entscheiden, ob Sie das Buch kaufen wollen oder nicht.
Unsere Suchtipps für Ihre Suche:
- Alle Bücher des Autors.: Suche nach "Autor: sciences health policy" liefert mehr Ergebnisse
- Suchen nach Suchbegriffen wie Autor oder Titel des Buches sind erfolgreicher als solche nach der ISBN.: Suche nach "strengthening tuberculosis developing sciences health policy" liefert mehr Ergebnisse
Sie haben jetzt folgende Möglichkeiten:
- Speichern Sie diese Seite in Ihren Lesezeichen oder Favoriten ab, dann können Sie jederzeit die Suche erneut ausführen.
- Das Buch ist tatsächlich derzeit vergriffen bzw. nicht lieferbar. Es ist z.B. eine Rarität. Möglicherweise ist es aber in einiger Zeit lieferbar. Speichern Sie dazu diese Suche kostenlos ab oder lassen Sie sich kostenlos auf dieses Gerät benachrichten und Sie werden automatisch per E-Mail oder Nachricht informiert, sobald dieses Buch wieder lieferbar wird. Wir sind zuversichtlich, dass wir jedes Buch auf diese Weise innerhalb relativ kurzer Zeit finden. Probieren Sie es einfach aus!
Mich bei neuen Ergebnissen benachrichtigenSuche jetzt kostenlos SpeichernIn 50 Millionen auch bereits vergriffenen Büchern recherchieren!
Anmeldung mit Google:
ODER
Anmeldung mit Facebook:
Lade…